- Home
- ATXG vs VIVS Comparison
ATXG vs VIVS Comparison
Compare ATXG & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXG
- VIVS
- Stock Information
- Founded
- ATXG 2014
- VIVS 2007
- Country
- ATXG China
- VIVS United States
- Employees
- ATXG N/A
- VIVS N/A
- Industry
- ATXG Professional Services
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ATXG Consumer Discretionary
- VIVS Health Care
- Exchange
- ATXG Nasdaq
- VIVS Nasdaq
- Market Cap
- ATXG 4.0M
- VIVS 4.2M
- IPO Year
- ATXG N/A
- VIVS N/A
- Fundamental
- Price
- ATXG $0.60
- VIVS $1.45
- Analyst Decision
- ATXG
- VIVS
- Analyst Count
- ATXG 0
- VIVS 0
- Target Price
- ATXG N/A
- VIVS N/A
- AVG Volume (30 Days)
- ATXG 1.6M
- VIVS 64.3K
- Earning Date
- ATXG 08-13-2025
- VIVS 07-07-2025
- Dividend Yield
- ATXG N/A
- VIVS N/A
- EPS Growth
- ATXG N/A
- VIVS N/A
- EPS
- ATXG N/A
- VIVS N/A
- Revenue
- ATXG $4,549,310.00
- VIVS $144,000.00
- Revenue This Year
- ATXG N/A
- VIVS $42.38
- Revenue Next Year
- ATXG N/A
- VIVS $15.42
- P/E Ratio
- ATXG N/A
- VIVS N/A
- Revenue Growth
- ATXG N/A
- VIVS 32.11
- 52 Week Low
- ATXG $0.49
- VIVS $1.41
- 52 Week High
- ATXG $1.86
- VIVS $21.96
- Technical
- Relative Strength Index (RSI)
- ATXG 38.42
- VIVS N/A
- Support Level
- ATXG $0.58
- VIVS N/A
- Resistance Level
- ATXG $0.75
- VIVS N/A
- Average True Range (ATR)
- ATXG 0.07
- VIVS 0.00
- MACD
- ATXG -0.01
- VIVS 0.00
- Stochastic Oscillator
- ATXG 5.19
- VIVS 0.00
About ATXG Addentax Group Corp.
Addentax Group Corp is an investment holding company. The company through its operating subsidiaries functions in the following segments; Garment manufacturing; Logistics services; Property management and subleasing. It generates maximum revenue from the Logistics services segment which provides logistics services including storage, transportation, warehousing, handling, packaging, and order processing. It also provides customs declaration and tax clearance services to its customers who export goods overseas. Geographically, the company derives all of its revenue from China.
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.